Fenoxazoline

Fenoxazoline

SCHEMBL193061

CC(C)c1ccccc1OCC1=NCCN1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 12/20 1.00
HTR1A P08908 4/20 0.63
ADRA2A P08913 4/20 0.63
ADRA2B P18089 4/20 0.63
ADRA2C P18825 4/20 0.63
ADRA1A P35348 6/20 0.60
ADRA1B P35368 5/20 0.60
ADRA1D P25100 4/20 0.60
MAOA P21397 3/20 0.60
MAOB P27338 3/20 0.60
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
THRB P10828 1/20 0.59
TSHR P16473 1/20 0.59
CYP2C19 P33261 1/20 0.59
THPO P40225 1/20 0.59
HSD17B10 Q99714 1/20 0.59
LMNA P02545 1/20 0.58
TAAR1 Q96RJ0 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenoxazoline SCHEMBL1650113 0.99 NISCH (0.97) NISCHHTR1AADRA2AADRA2BADRA2C
Fenoxazoline SCHEMBL317133 0.99 NISCH (0.97) NISCHHTR1AADRA2AADRA2BADRA2C
Tymazoline SCHEMBL28142132 0.90 NISCH (0.81) NISCHHTR1AADRA2AADRA2BADRA2C
Fenoxazoline SCHEMBL28086604 0.86 NISCH (0.74) NISCHHTR1AADRA2AADRA2BADRA2C
Tymazoline SCHEMBL29387735 0.82 NISCH (0.70) NISCHHTR1AADRA2AADRA2BADRA2C
Tymazoline SCHEMBL250491 0.82 NISCH (0.70) NISCHHTR1AADRA2AADRA2BADRA2C
Tymazoline SCHEMBL4415590 0.81 NISCH (0.68) NISCHHTR1AADRA2AADRA2BADRA2C
SCHEMBL3168567 0.81 NISCH (0.73) NISCHHTR1AADRA2AADRA2BADRA2C
SCHEMBL3169242 0.78 NISCH (0.68) NISCHHTR1AADRA2AADRA2BADRA2C
SCHEMBL546268 0.75 NISCH (0.78) NISCHHTR1AADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114500226-A HTTP response failover in HTTP scenarios on ICN IDAC控股公司 2022-05-13 CN claimed
EP-3331650-B1 METHOD OF MANUFACTURING A VIBRATABLE HEAD FOR AN AEROSOL GENERATOR AND VIBRATABLE HEAD FOR AN AEROSOL GENERATOR PARI PHARMA GMBH (DE) 2020-09-30 EP claimed
US-20170196904-A1 SILICONE OIL-CONTAINING FORMULATIONS FOR NASAL APPLICATION INQPHARM GROUP SDN BHD (DE) 2017-07-13 US claimed
CN-106659734-A Silicone oil-containing formulations for nasal application INQ制药集团有限公司 2017-05-10 CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-2731606-A1 GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE Allergan, Inc. (US) 2014-05-21 EP claimed
CN-103796652-A Gel compositions of oxymetazoline and methods of use ALLERGAN INC 2014-05-14 CN claimed
US-20130079379-A1 GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE ALLERGAN, INC. (US) 2013-03-28 US claimed
WO-2013028909-A1 COMBINATION THERAPY FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS SOVA PHARMACEUTICALS, INC. (US) 2013-02-28 WO claimed
WO-2013010032-A1 GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE ALLERGAN, INC. (US) 2013-01-17 WO claimed
EP-0903151-A1 Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms ASTA Medica Aktiengesellschaft (DE) 1999-03-24 EP claimed
EP-0550921-B1 Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug ZAMBON SPA (IT) 1999-03-17 EP claimed
US-5334138-A Drug delivery; mixture of active material and vasoconstrictor NORTH CAROLINA STATE UNIVERSITY (US) 1994-08-02 US claimed
EP-0448299-B1 Composition for increased skin concentration of active agents by iontophoresis BECTON DICKINSON CO (US) 1994-06-01 EP claimed
EP-0550921-A1 Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug ZAMBON GROUP S.p.A. (IT) 1993-07-14 EP claimed
EP-0276761-B1 LATCH DEVICE FOR INCLINABLE BACK REST CUSHION MOUNTED IN SEATBACK Ikeda Bussan Co., Ltd. (JP) 1992-06-17 EP claimed
EP-0487804-A1 Deflection yoke THOMSON TUBES & DISPLAYS SA (FR) 1992-06-03 EP claimed
EP-0448299-A2 Composition for increased skin concentration of active agents by iontophoresis Becton, Dickinson and Company (US) 1991-09-25 EP claimed
EP-0276761-A2 Latch device for inclinable back rest cushion mounted in seatback Ikeda Bussan Co., Ltd. (JP) 1988-08-03 EP claimed
US-4353600-A Non-linkage type load sensing valve NISSAN MOTOR CO., LTD. (JP) 1982-10-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079379-A1 GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE CUTA, PDE3A, PTGIS NISCH 586/4885HTR1A 622/4885ADRA2A 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.